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Farzin Fakhry, MSc,a,b Koen M. van de Luijtgaarden, MD,c Leon Bax, PhD,d
P. Ted den Hoed, MD, PhD,e M. G. Myriam Hunink, MD, PhD,a,b Ellen V. Rouwet, MD, PhD,c and
Sandra Spronk, PhD,a,b Rotterdam, The Netherlands; and Sunnyvale, Calif
Objective: Exercise therapy is a common intervention for the management of intermittent claudication (IC). However,
considerable uncertainty remains about the effect of different exercise components such as intensity, duration, or content
of the exercise programs. The aim of this study was to assess the effectiveness of supervised walking therapy (SWT) as
treatment in patients with IC and to update and identify the most important exercise components resulting in an optimal
training protocol for patients with IC.
Methods: A systematic literature search using MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials
databases was performed. Randomized controlled trials (RCTs) published between January 1966 and February 2012
were included if they evaluated the effectiveness of SWT. Predefined exercise components were extracted, including
treadmill use during training, claudication pain end point used during walking, length of the SWT program, and total
training volume. A meta-analysis and meta-regression was performed to evaluate the weighted mean difference in
maximum walking distance (MWD) and pain-free walking distance (PFWD) between SWT and noninterventional
observation.
Results: Twenty-five RCTs (1054 patients) comparing SWT vs noninterventional observation showed a weighted mean
difference of 180 meters (95% confidence interval, 130-230 meters) in MWD and 128 meters (95% confidence interval,
92-165 meters) in PFWD, both in favor of the SWT group. In multivariable meta-regression analysis, none of the
predefined exercise components were independently associated with significant improvements in MWD or PFWD.
Conclusions: SWT is effective in improvingMWD and PFWD in patients with IC. However, pooled results from the RCTs
did not identify any of the exercise components including intensity, duration, or content of the program as being
independently associated with improvements in MWD or PFWD. (J Vasc Surg 2012;56:1132-42.)
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iPeripheral arterial disease (PAD) is prevalent in West-
ern countries, affecting4.3% of the population aged40
years and increases with age to 14.5% in the elderly popu-
lation aged 70 years.1 Intermittent claudication (IC), a
common manifestation of PAD, defined as muscle discom-
fort in the legs that is elicited by exercise and relieved by a
short period of rest, is associated with significant functional
disability, reduced quality of life,2 and an increased risk for
nonfatal and fatal cardiovascular events.3
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1132Treatment strategies for IC include pharmacotherapy,4
hysical exercise therapy,5 and surgical or percutaneous
ascular interventions.6,7 Considerable evidence is available
o suggest that exercise therapy should have a central role in
he management of IC by significantly improving the pain-
ree walking distance (PFWD) and maximum walking dis-
ance (MWD) and lowering the risk for cardiovascular
vents.5,8 In particular, supervised exercise therapy, which
sually involves walking on a treadmill, is considered more
ffective than unsupervised exercise therapy,9,10 and there-
ore, the general consensus is to initially treat patients with
C with supervised exercise therapy.6,7
Although supervision and (treadmill) walking are con-
idered important components of the exercise program, a
ot of uncertainty remains about the intensity, duration,
nd content of the programs. In a 1995 meta-analysis,
ardner et al11 determined the most important exercise
omponents for providing optimal improvements in walk-
ng ability in patients with IC. The authors concluded that
he optimal exercise program consists of intermittent walk-
ng to near-maximal pain for a period of at least 6 months.
owever, these recommendations were based on results
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Volume 56, Number 4 Fakhry et al 1133from nonrandomized (un)controlled studies. Since this
publication 16 years ago, many randomized controlled
trials (RCTs) evaluating the effectiveness of supervised
walking therapy (SWT) programs with a great variety in
exercise protocols have been published. In addition, new
methodologic evidence about meta-analytic approaches is
available, and experience has accumulated since the last
meta-analysis on this topic.
Therefore, the primary aim of this study was to deter-
mine whether SWT in patients with IC is effective in
improving MWD and PFWD, and secondly, to update and
identify the components of SWT that provide maximal
improvement inMWD and PFWD. Implementation of this
state-of-the-art systematic review andmeta-analysis of SWT
Fig 1. Flow diagram of studies identified fromprograms may optimize the therapeutic benefits of SWT as dnoninvasive first-line treatment in the large population of
atients with IC.
ETHODS
Data sources. Two authors (F.F., K.L.) collaborated
ith a professional librarian to independently develop mul-
iple search strategies to identify RCTs, which evaluated
WT in patients with IC, published between January 1966
nd February 2012.We first performed an electronic search
nMEDLINE and EMBASE. This search was subsequently
eproduced using the Cochrane Central Register of Con-
rolled Trials Register of Controlled Trials. Relevant key-
ords relating to disease of interest (claudica* and inter-
itten* or vascular disease* or peripheral arterial occlusive
ture search. SWT, Supervised walking therapy.isease* or peripheral arterial disease* or peripheral artery
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in combination with keywords relating to exercise program
(exercise or exercise or training or walking or gymnast*)
using a Boolean search strategy. Reference lists of all eligi-
ble studies were hand-searched for additional studies, and
no language restriction was applied.
Study selection. Identified studies were initially se-
lected by a review of titles and abstracts by three reviewers
(K.L., E.R., and S.S) independently. Final selection was
based on a full-text evaluation of the selected studies by two
reviewers (F.F., S.S.) independently. Disagreements be-
tween the reviewers were discussed and resolved by consen-
sus. Studies were included if they were (1) an RCT com-
paring SWT and noninterventional observation in patients
with IC and (2) assessed PFWD or MWD, or both, or time
using a treadmill test before and after SWT.
When data from the same patient population were
published in various journals, we examined the results and
included the data only once in our systematic review.
Quality assessment. Methodologic quality of the in-
cluded studies was assessed using the Physiotherapy Evi-
dence Database (PEDro) scale.12 The following quality
criteria are included and rated in the PEDro score: eligibil-
ity criteria specified, randomization of subjects, concealed
allocation, baseline similarity of groups regarding the most
important prognostic indicators, blinding of subjects,
Table I. Characteristics of the randomized controlled trial
First author Year
Study
location
Treatment
group
Dahllof19 1974 Sweden SWT plusc
Hiatt20 1990 U.S. SWT
Jansen21 1991 Germany SWT
Hiatt22 1994 U.S. SWT
Tisi23 1997 U.K. SWT
Gibellini24 2000 Italy SWT
Gardner25 2001 U.S. SWT
Gelin26 2001 Sweden SWT
Gardner27 2002 U.S. SWT
Langbein28 2002 U.S. Pole-striding
Tsai29 2002 Taiwan SWT
Mika30 2005 Poland SWT
Sandri31 2005 Germany SWT
Hobbs32 2006 U.K. SWT plusc
Mika33 2006 Poland SWT
Sanderson34 2006 Australia SWT
Wood35 2006 Australia SWT
Hobbs36 2007 U.K. SWT plusc
Crowther37 2008 U.S. SWT
Hodges38 2008 U.K. SWT
Treat-Jacobson39 2009 U.S. SWT
Schlager40 2011 Austria SWT
Leicht41 2011 Australia SWT
Gardner42 2011 U.S. SWT
Mika43 2011 Poland SWT
NR, Not reported; SWT, supervised walking therapy; U.K., United Kingdo
aData presented as mean  standard deviation.
bPEDro Score: Physiotherapy EvidenceDatabase scale is a tool to assess them
0 and 10).
cTherapy consisted of walking combined with additional lower limb aerobicblinding of therapists, blinding of assessors, completenessf follow-up, outcomes analyzed by intention-to-treat
rinciple, between-group statistical comparison reported,
nd point measures and measure of variability reported.
Data extraction. One reviewer (F.F.) extracted all
equired data from each included study using a standard-
zed form that consisted of (1) study characteristics, includ-
ng year of publication, study location, and number of
atients in each group; (2) patient baseline characteristics,
ncluding mean age and sex; and (3) primary outcomes,
ncluding MWD and PFWD before and after SWT. If the
alking performance was reported in a unit of time, this was
onverted to walking distances by using the reported tread-
ill speed.
To evaluate SWT we recorded the following compo-
ents from each program:
● Mode of exercise, defined as “walking” or “walking
plus,” which was a combination of walking and alter-
native modes of exercises, including heel raises, knee
bends, step-ups, and arm exercises, among others;
● Treadmill use during training;
● Length of walking program in weeks;
● Number of sessions per week;
● Duration of each session in minutes; and
● Pain end point used during walking, which was defined
as PFW, walking to mild or moderate claudication
luded in the systematic review
ntrol group
Patients
(No.)
Male
(%)
Agea
(years)
PEDro
scoreb
ebo tablets 18 72 61  5 4
intervention 19 100 60  12 4
intervention 48 NR NR 4
intervention 20 100 67  6 5
ice to walk 39 69 68  NR 5
intervention 40 90 67  7 3
intervention 52 91 71  1 6
intervention 177 67 67  NR 5
intervention 31 NR 72  1 5
intervention 52 98 67  9 5
intervention 53 83 76  4 5
intervention 80 83 61  6 5
intervention 18 NR 57  2 5
intervention 14 71 72  NR 5
intervention 55 87 59  8 6
intervention 27 59 61  8 6
intervention 13 69 60  8 4
intervention 18 78 67  NR 5
intervention 21 47 69  8 5
ice to walk 28 NR 68  8 3
ice to walk 19 71 67  10 5
intervention 40 60 69  10 7
intervention 25 56 67  8 5
intervention 79 49 66  11 5
intervention 68 88 63  7 5
S., United States.
ological quality of the included randomized controlled trials (score between
ises.s inc
Co
Plac
No
No
No
Adv
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Adv
Adv
No
No
No
No
m; U.
ethodpain, or walking to (near) maximum claudication pain.
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SWT program (in minutes), was calculated by multiplying
the length of the program (in weeks), number of sessions
per week, and duration per session (in minutes).
Data analysis. The primary and secondary outcomes
of interest were the weighted mean difference inMWD and
PFWD between the SWT and control groups. Mean post-
training MWD and PFWD from each trial were combined
and weighted in a meta-analysis using a DerSimonian and
Laird random effects model to estimate the pooled effect of
Table II. Characteristics of supervised walking therapy fro
Author Year
Mode of
exercise
Treadmill
used
during
SWT?
Walking pai
end point
Dahllof19 1974 Walking plusb No Mild/moderate
Hiatt20 1990 Walking Yes Mild/moderate
Jansen21 1991 Walking Yes Mild/moderate
Hiatt22 1994 Walking Yes Mild/moderate
Tisi23 1997 Walking No Maximum pain
Gibellini24 2000 Walking Yes Pain free
Gardner25 2001 Walking Yes Maximum pain
Gelin26 2001 Walking No Mild/moderate
Gardner27 2002 Walking Yes Maximum pain
Langbein28 2002 Pole-striding No Maximum pain
Tsai29 2002 Walking Yes Mild/moderate
Mika30 2005 Walking Yes Pain free
Sandri31 2005 Walking Yes Maximum pain
Hobbs32 2006 Walking plusb No Mild/moderate
Mika33 2006 Walking Yes Pain free
Sanderson34 2006 Walking Yes Mild/moderate
Wood35 2006 Walking Yes Mild/moderate
Hobbs36 2007 Walking plusb No Mild/moderate
Crowther37 2008 Walking Yes Maximum pain
Hodges38 2008 Walking Yes Maximum pain
Treat-Jacobson39 2009 Walking Yes Maximum pain
Schlager40 2011 Walking Yes Mild/moderate
Leicht41 2011 Walking Yes Maximum pain
Gardner42 2011 Walking Yes Maximum pain
Mika43 2011 Walking Yes Pain free
SWT, Supervised walking therapy.
aTraining volume: Total duration SWT program  Length program times (
bWalking plus: Therapy consisted of walking combined with additional lowthe outcomes. These estimates were expressed as a deighted mean difference in MWD and PFWD, including
5% confidence intervals (95% CI).13 Statistical heteroge-
eity was assessed for the mean differences in MWD and
FWD by calculating the Q statistics and the I2 statistic.
Selective dissemination of evidence was assessed by
lotting for each study the weighted mean difference in
WD and PFWD, against precision (1/standard error) in
plot with P value contours. Funnel plot asymmetry,
pecifically with apparent absent of studies in high P value
reas of the plot, can be indicative of selective evidence
ch study included in the systematic review
Length
program
(weeks)
Sessions/week
(No.)
Duration
each session
(minutes)
Training
volumea
(minutes)
26 3 30 2340
12 3 60 2160
104 2 120 24,960
12 3 60 2160
4 1 60 240
4 10 30 1200
26 3 60 4680
52 0-26 wks: 3 sessions 30 3900
27-52 wks: 2 sessions
78 0-26 wks: 3 sessions
27-78 wks: 2 sessions
0-26 wks: starting
with 15 minutes
increased with 5
min per mon.
6423
27-52 wks: 40 min
20 0-4 wks: 3 sessions 60 2040
5-12 wks: 2 sessions
13-16 wks: 1 session
16-20 wks: 1 session/2 wks
12 3 40 1440
12 3 60 2160
4 5 days/wk 6 sessions
daily
2 times walking
until maximal
claudication pain
with 2 minutes
rest in between
(10 min/
session)
1200
12 2 60 1440
12 3 60 2160
6 3 40 720
6 3 40 720
12 2 60 1440
52 3 25-40 5070
12 2 45 1080
12 3 70 2520
26 2 60 3120
52 3 25-40 5070
12 3 Starting with 15
min increased
with 5min/2 wks
990
12 3 Starting with 30
min increased
with 5min/2 wks
1530
e) number of sessions per week times (average) duration per session.
b aerobic exercises.m ea
n
pain
pain
pain
pain
pain
pain
pain
pain
pain
pain
painissemination.14 Funnel plot asymmetry was formally eval-
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tion of selective evidence dissemination, we performed a
“trim and fill” procedure by imputing the potentially miss-
ing studies and checking whether this would change our
results significantly.17
The heterogeneity of the weighted mean differences in
MWD and PFWD between the SWT programs and the
potential effect of SWT program components on this het-
erogeneity was first investigated by performing a subgroup
meta-analysis of each SWT program component separately.
Then, a multivariable random effects meta-regression model
was used to determine whether an individual SWT compo-
nent or a combination of components would significantly
explain the variation between the studies and thus was/
were independently associated with improvement in MWD
and PFWD.
Individual study effect on the results was evaluated by
an exclusion sensitivity analysis. In addition, sensitivity
analysis by removing studies with a PEDro score 4 was
performed to observe whether removing RCTs with a very
low PEDro score would significantly change the results.
A two-sided P  .05 was considered statistically signif-
icant, except for the tests for selective evidence dissemina-
tion, for which the recommended levels are P  .10.
Table III. Results of the randomized controlled trials incl
First author Year
Patients a
Intervention
Dahllof19 1974 10
Hiatt20 1990 10
Jansen21 1991 24
Hiatt22 1994 10
Tisi23d 1997 22
Gibellini24 2000 20
Gardner25 2001 28
Gelin26 2001 73
Gardner27 2002 17
Langbein28 2002 27
Tsai29 2002 27
Mika30 2005 41
Sandri31 2005 9
Hobbs32e 2006 7
Mika33 2006 27
Sanderson34 2006 13
Wood35 2006 7
Hobbs36 2007 9
Crowther37 2008 10
Hodges38 2008 14
Treat-Jacobson39 2009 11
Schlager40 2011 20
Leicht41 2011 8
Gardner42 2011 33
Mika43 2011 30
MWD, Maximum walking distance; NR, not reported; PFWD, pain-free wa
aData are presented as mean  standard deviation or median (interquartile
bIn the placebo-treated control patients, the walking distance remained unc
cMean change in walking distance after SWT.
dReported post-training distances after 12-month follow-up.
eReported post-training distance after 6-month follow-up.Analyses were performed using SPSS 17 software (SPSS wnc, Chicago, Ill), STATA 12 (StataCorp, College Station,
ex), and MIX Professional 2.0.18
ESULTS
iterature search
From the original electronic search, 2778 citations
ublished between January 1966 and February 2012 were
etrieved (Fig 1). Of these, 992 studies were excluded
ecause they were duplicates, and 1746 studies were ex-
luded after the titles and abstracts were reviewed. Subse-
uently, of the 40 selected studies for full text review,
nother 15 studies were excluded for failing to meet pre-
efined criteria (Fig 1); finally, 25 RCTs19-43 met our
nclusion criteria and were included in the analysis.
tudy characteristics
The selected RCTs included 1054 patients (76%male),
ith studies ranging in sample size from 13 to 177 patients.
he mean patient age was 66.0  7.0 years (Table I).
wenty-four RCTs offered SWT-plus as intervention,
hereas one RCT offered a supervised pole-striding program
o the intervention group. The control groups in three RCTs
in the systematic reviewa
ed MWD (m) SWT group
Control Pretraining Post-training
8 296  150 620  160
9 341  91 741  187
24 191  27 320  50
8 515  306 789  392
17 104 (72-148) 175 (103-258)
20 217  79 451  170
24 396  211 702  279
76 258  142 247  111
14 425  139 800  445
25 505  433 1420  1156
26 397  209 671  199
39 NR NR
9 152  34 210  47
7 111 (69-237) 124 (74-352)
28 408  56 609  74
14 NR 180  46c
6 686  400 905  375
9 99 (81-241) 218 (122-339)
11 300  125 661  278
14 347  219 622  310
8 483  291 295  164c
20 102 (66-155) 154 (97-230)
9 NR 296  150
33 289  150 480  250
31 551  57 848  61
distance; SWT, supervised walking therapy.
.
d.uded
nalyz
lking
range)
hangeere advised to walk as much as possible at home, but no
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one RCT received placebo tablets (Table I).
Quality assessment
The methodologic quality of the included RCTs ac-
cording to the PEDro scale is presented in Table I. Eight
RCTs (32%) reported a proper concealment of randomiza-
tion, whereas 18 (72%) reported baseline similarity be-
tween the intervention and control groups. None of the
RCTs blinded the participants or the therapists who admin-
istrated the therapy, and only four RCTs (16%) reported
blinding the assessors who measured one or more out-
comes. In 17 RCTs (68%), measurement of at least one key
outcome was obtained from85% of the participants initially
allocated to groups, and only five (20%) reported outcome
analysis according to the intention-to-treat principle. Yet, 23
RCTs (92%) performed and reportedbetween-group statistics
for the main outcomes, and all included RCTs reported point
measurements andmeasurements of variability for at least one
of the key outcomes.
Overall, the methodologic quality of the included
RCTs was low, with an average PEDro score of 5 of 10
points. However, due to the nature of the comparison
(SWT vs no exercise) in the RCTs, it was impossible to
Table III. Continued.
MWD (m) control group PFWD
Pretraining Post-training Pretraining
340  253 340  253b 91  35
320  107 379  155 NR
145  16 171  25 116  14
395  176 389  144 177  107
110 (81-148) 126 (104-156) 70 (45-87)
230  110 226  123 128  46
379  254 425  296 172  127
272  153 261  131 NR
430  139 425  278 195  139
535  184 499  226 NR
384  171 405  203 177  166
NR NR 87  38
148  51 146  38 104  34
84 (79-227) 145 (75-435) 59 (35-63)
382  63 401  68 178  32
NR 8  41c 309  188
966  596 1019  626 284  197
94 (79-162) 137 (94-175) 60 (45-95)
252  163 309  183 119  55
362  240 405  359 NR
361  186 45  93c 200  151
85 (50-150) 100 (40-150) NR
NR 244  172 NR
449  192 439  213 174  128
551  62 516  89 260  52blind the subjects and therapists for the randomized (roups; therefore, the maximum PEDro score that could
e achieved by the RCTs was 8 points.
WT program characteristics
Walking was the only mode of exercise used in 21
CTs, a combination of walking and additional lower limb
erobic exercises was used in three RCTs, and pole-striding
as used as the mode of exercise in the intervention group
n one RCT. Patients in 10 RCTs exercised till (near)
aximum claudication pain before taking a short rest dur-
ng the walking sessions, patients in 11 studies walked till
ild/moderate claudication pain, and patients in four
tudies exercised pain free. Treadmill walking during the
xercise sessions was reported in 19 of 25 programs (Table
I). The total length of SWT programs included varied
etween 4 and 104weeks, with 60% of the programs lasting
etween 12 and 26 weeks. An average of four training
essions were held weekly, with an average duration of 49
inutes per session (range, 10-120 minutes; Table II).
ffect of SWT on walking distance
Twenty-four RCTs reported MWD measurements be-
ore and after training from the intervention and control
roups, and 20 RCTs also reported PFWD measurements
WT group PFWD (m) control group
Post-training Pretraining Post-training
230  100 55  119 55  119b
NR NR NR
196  26 89  9 111  13
360  231 203  123 165  69
112 (103-253) 80 (44-91) 107 (67-137)
308  163 112  65 111  79
402  274 163  122 203  228
NR NR NR
580  445 190  139 210  178
NR NR NR
333  145 155  139 171  181
192  95 87  40 102  50
175  51 98  59 87  47
92 (47-169) 47 (30-118) 56 (45-325)
359  56 181  18 187  25
455  277 293  308 335  332
456  302 236  143 296  156
110 (66-194) 59 (48-72) 73 (46-80)
322  168 103  88 148  80
NR NR NR
92  148c 119  62 4  45c
NR NR NR
116  58 NR 107  93
321  235 200  140 186  149
542  72 258  71 258  89(m) STable III). The weighted mean difference in MWD from
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October 20121138 Fakhry et al24 RCTs comprising 916 patients was 180meters (95% CI,
130-230 meters), which was statistically significant in favor
of SWT compared with noninterventional observation (Fig
2). Similarly, the weighted mean difference in PFWD from
20 RCTs comprising 708 patients was statistically signifi-
cant, with 128 meters (95% CI, 92-165 meters) in favor of
the SWT group (Fig 3).
Assessment of selective evidence dissemination
The funnel plots (Fig 4 and Fig 5), the Begg tests, and
the Egger regression tests were all suggestive of potential
selective dissemination bias. The “trim and fill” correction
changed the weighted mean differences in MWD and
PFWD to 148 (95% CI, 136-160 meters) and 97 meters
(95% CI, 92-165 meters), respectively, both still in favor of
SWT.
Association between SWT components and walking
distance
Subgroup analysis. In subgroup meta-analysis, SWT
programs selected by their predefined components showed
statistically significant improvements in MWD and PFWD
compared with their control groups, except for studies in
which no treadmill was used during the SWT and the total
SWT volume was 1080 minutes (Table IV).
Multivariable meta-regression. Multivariable ran-
dom effects meta-regression, which included all the SWT
components listed in Table IV as covariables, indicated that
only a small fraction of the heterogeneity in the weighted
mean difference in MWD or PFWD between the included
Fig 2. Mean difference in maximum walking distance (
vised walking therapy (SWT) vs noninterventional obserRCTs could be explained by the covariables entered in the iandom effects meta-regression model. In other words,
one of the entered components from SWT programs were
ndependently associated with the improvements in MWD
r PFWD.
None of the studies had excessive effect on the results,
s evaluated by an exclusion sensitivity analysis. Further-
ore, sensitivity analysis by removing studies with a PEDro
core 4, did not have a major effect on the results.
ISCUSSION
We evaluated the effectiveness of SWT as initial treat-
ent in patients with IC by performing a systematic review
nd meta-analysis of RCTs that compared SWT with non-
nterventional observation. In addition, we performedmul-
ivariable meta-regression to identify the most important
xercise components in SWT programs.
Results from our meta-analysis, based on RCTs com-
aring SWT with noninterventional observation, demon-
trated that SWT is associated with significantly greater
mprovement in both MWD and PFWD. These results are
onsistent with two previous systematic reviews that dem-
nstrated that supervised exercise therapy improves walk-
ng distance compared with unsupervised exercise therapy9
r usual care.10 We only included RCTs evaluating walking
rograms and excluded other modes of exercise therapies,
uch as strength training, cycling, pneumatic calf compres-
ion, and upper limb exercises, to make the exercise studies
ore comparable.
In multivariable meta-regression, none of the exer-
ise components, including treadmill use during train-
) from randomized controlled trials comparing super-
. CI, Confidence interval; SD, standard deviation.MWDng, claudication pain end point used during walking,
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seemed to be independently associated with significant
mean improvements in MWD or PFWD. Yet in subgroup
analysis, there seemed to be a tendency to greater mean
improvement in MWD and PFWD in SWT programs
with a middle-term length (12-26 weeks) compared with
the shorter (12 weeks) or longer (26 weeks) pro-
grams. This tendency was also observed in total training
volume (Table IV). This suggests that SWT between 12
and 26 weeks, with three sessions per week and 30
Fig 3. Mean difference in pain-free walking distance (P
vised walking therapy (SWT) vs noninterventional obser
Fig 4. Heterogeneity funnel plot of the mean difference in max-
imum walking distance (MWD) from the included randomized
controlled trials.minutes of walking per session, would give the best Aesults. However, these results were not confirmed by
eta-regression analysis and need to be evaluated prop-
rly in an RCT.
A meta-analysis based on RCTs to evaluate the effect of
arious exercise components on clinical improvement is
ifficult, given the lack of RCTs directly comparing differ-
nt exercise components. In a previous systematic review
rom 1995 that combined results from RCTs and uncon-
rolled studies, Gardner et al11 determined that the optimal
xercise program for patients with IC consists of intermit-
ent walking to near-maximal pain for at least 6 months.
) from randomized controlled trials comparing super-
. CI, Confidence interval; SD, standard deviation.
ig 5. Heterogeneity funnel plot of the mean difference in pain-
ree walking distance (PFWD) from the included randomized
ontrolled trials.FWDlthough the present systematic review used results from
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due to selection bias, our results do not support these
prior recommendations: no single exercise component
was independently associated with a significant improve-
ment in walking distance. In line with the present study,
a more recent review by Parmenter et al44 on the same
topic concluded that improvements in MWD were not
related to various components of exercise training; how-
ever, the focus in the review by Parmenter et al was not
on SWT but on any mode of exercise therapy for patients
with IC.
The recommended supervised exercise therapy pro-
grams,6,7 consisting of walking 30 to 60 minutes to (max-
imum) claudication pain three to five times weekly for a
duration of 3 to 6 months, are usually experienced as very
intensive and time-consuming. Consequently, these rec-
ommended programs are affiliated with low patient com-
pliance and high dropout rates.45
In addition to improving walking ability, exercise train-
ing is also effective in preventing cardiovascular events,8,46
and this can fulfill an important role in cardiovascular risk
factor management in patients with IC by encouraging
patients to quit smoking and adhere to prescribed medica-
tion. Hence, every attempt to increase patient compliance
with SWT programs should be considered and evaluated
carefully. The results of this systematic review suggest that
a low-intensity (pain-free) SWT or a shorter training
duration, or both, might be as equally beneficial as high-
intensity exercise programs with a relatively long duration,
while promoting patient compliance with the SWT. How-
ever, clinical RCTs evaluating each component from SWT
independently are essential to determine the optimal SWT
protocol, resulting in improvement in walking distance and
higher patient compliance.
A full economic evaluation of the SWT components
from patient and societal perspectives is necessary to deter-
Table IV. Weighted mean changes in MWD and PFWD s
Component SWT program
Studies
(No.)
Change in M
(meters
Pain end point
Pain free 3 257 (164-
Mild/moderate pain 11 151 (85-2
Maximum pain 10 177 (97-2
Length SWT program (weeks)
Short-term (4-11) 5 123 (41-2
Medium-term (12-26) 14 223 (149-
Long-term (26) 5 145 (27-2
Total program volume (minutes)
0-1080 5 105 (6-20
1081-2340 11 237 (151-
2340 8 154 (72-2
Treadmill use during SWT
No 6 100 (2-19
Yes 18 200 (150-
MWD, Maximum walking distance; PFWD, pain-free walking distance; SW
aData are presented as mean (95% confidence interval).mine the cost-effectiveness of different SWT programs. van ssselt et al47 evaluated the cost-effectiveness of supervised
xercise therapy compared with “go home andwalk” advice
nd concluded that at the willingness-to-pay threshold of
40,000 per quality-adjusted life-year, exercise therapy is
ikely to be a cost-effective treatment option. This was
ased on exercise therapy consisting of two to three ses-
ions of 30 minutes weekly for 1 year, the frequency of
hich could be adjusted depending on the patient’s prog-
ess and need. The remaining question is whether a less
ntensive SWT program is going to be cost-effective com-
ared with the recommended SWT programs at regular
ntensity.
Some limitations of this systematic review should be
ddressed. The results of the systematic review are limited
y the methodologic quality of the original studies. The
ean PEDro score was low (average, 5 points), with most
tudies not reporting allocation concealment or data anal-
sis according to the intention-to-treat principle. The sam-
le size of the included studies was relatively small (average,
2 patients), which might have resulted in lack of statistical
epresentation or precision in effect estimation. Negative or
onsignificant studies with low precision seem to be miss-
ng in the funnel plot, which might be an indication of
elective reporting or publication. Still, performing a “trim
nd fill” procedure by imputing the potentially missing
tudies did not change our results significantly. Another
ssue was missing data, especially data on compliance or
dherence to the SWT programs were lacking. Next, the
tudies did not use similar standardized treadmill tests to
ssess the walking distances before and after SWT. The
ecommendation is to use a standardized progressive tread-
ill test with a constant walking speed of 3.2 km/h and
radual increase in inclination of 2% every 2 minutes till a
aximum grade of 10%.48 However, most of the included
tudies used other treadmill test protocols with varying
by supervised walking therapy program component
a
P
Studies
(No.)
Change in PFWDa
(meters) P
.01 4 128 (92-165) .01
.01 8 101 (63-140) .01
.01 8 100 (45-156) .01
.01 5 100 (20-179) .01
.01 11 146 (94-197) .01
.02 4 109 (27-190) .01
.04 4 128 (92-165) 0.1
.01 10 146 (95-198) .01
.01 6 111 (52-170) .01
.05 4 57 (13 to 126) .11
.01 16 128 (92-165) .01
ervised walking therapy.orted
WD
)
351)
17)
57)
04)
298)
63)
5)
323)
36)
9)
250)
T, suppeed and gradual incline of the treadmill, which might
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RCTs.
Results on the effectiveness of exercise programs from
our systematic review and previous systematic reviews are
based on pooled results from RCTs evaluating nonstan-
dardized exercise programs with very diverse training com-
ponents regarding duration, mode, and intensity of the
programs. Nevertheless, our results confirm the suggestion
that, despite the diversity in SWT, these studies have one
thing in common: they all show significant clinical benefits
for patients with IC independent of the frequency, dura-
tion, mode, or intensity of the programs.
CONCLUSIONS
This systematic review showed that SWT is effective in
improving MWD and PFWD in patients with IC. How-
ever, pooled results from the RCTs evaluating SWT pro-
grams did not identify a statistically significant association
between the improvements in MWD or PFWD and indi-
vidual SWT program components.
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